Home ProductsFITC-εAhx-Gly-Arg-Gly-Asp-Ser-Pro-OH

FITC-εAhx-Gly-Arg-Gly-Asp-Ser-Pro-OH

FITC-εAhx-Gly-Arg-Gly-Asp-Ser-Pro-OH thumbnail 1

GTR01195370

FITC-εAhx-Gly-Arg-Gly-Asp-Ser-Pro-OH

recombinant-pseudotuberculosis-yersinia

Supplier ID: 121

$197.28($260.90)

Size: 0.5 mg

Tuberculosis (TB) remains one of the leading causes of mortality worldwide, driven largely by delayed diagnosis and the emergence of drug-resistant strains. In recent years, the development and validation of biomarkers for tuberculosis have become central to improving early detection, disease monitoring, and therapy efficacy. Whether in the context of latent TB infection (LTBI) or active pulmonary TB, identifying reliable and reproducible biomarkers is a top priority in both clinical and research settings.

Pages

Home
Products
Withdrew Requests Form

[email protected] +4924193688188

© 2026 Biomarkers of Protective Immunity Against TB . All rights reserved.